<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490632</url>
  </required_header>
  <id_info>
    <org_study_id>14455</org_study_id>
    <secondary_id>I4V-MC-JADP</secondary_id>
    <nct_id>NCT01490632</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib
      in the treatment of participants with moderate to severe, chronic plaque psoriasis as
      assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety
      assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</measure>
    <time_frame>Week 24</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</measure>
    <time_frame>Week 92</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Baseline Part A, Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Baseline Part A, Week 24</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Baseline Part D, Week 92</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12</measure>
    <time_frame>Baseline Part A, Week 12</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24</measure>
    <time_frame>Baseline Part A, Week 24</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92</measure>
    <time_frame>Baseline Part D, Week 92</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12</measure>
    <time_frame>Baseline Part A, Week 12</time_frame>
    <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24</measure>
    <time_frame>Baseline Part A, Week 24</time_frame>
    <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92</measure>
    <time_frame>Baseline Part D, Week 92</time_frame>
    <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12</measure>
    <time_frame>Baseline Part A, Week 12</time_frame>
    <description>The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24</measure>
    <time_frame>Baseline Part A, Week 24</time_frame>
    <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92</measure>
    <time_frame>Baseline Part D, Week 92</time_frame>
    <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</measure>
    <time_frame>Baseline Part A, Week 12</time_frame>
    <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</measure>
    <time_frame>Baseline Part A, Week 24</time_frame>
    <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</measure>
    <time_frame>Baseline Part D, Week 92</time_frame>
    <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C</measure>
    <time_frame>Week 40</time_frame>
    <description>Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score &gt;125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib</measure>
    <time_frame>Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)</measure>
    <time_frame>Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Psoriasis</condition>
  <condition>Skin Diseases</condition>
  <condition>Skin Diseases, Papulosquamous</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib 2 mg</arm_group_label>
    <arm_group_label>Baricitinib 4 mg</arm_group_label>
    <arm_group_label>Baricitinib 8 mg</arm_group_label>
    <arm_group_label>Baricitinib 10 mg</arm_group_label>
    <other_name>LY3009104</other_name>
    <other_name>INCB028050</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must have active chronic plaque psoriasis for at least 6 months prior to entry
             into the study

          -  You are a candidate for systemic therapy and/or phototherapy

          -  You must have active plaque psoriasis covering at least 12% body surface area

          -  You must have Psoriasis Area and Severity Index (PASI) score of at least 12

          -  You must have Static Physician's Global Assessment (sPGA) score of at least 3

        Exclusion Criteria:

          -  You must not have received a biologic agent/monoclonal antibody within 8 weeks prior
             to entry into the study

          -  You must not have prior treatment with an oral Janus kinase (JAK) inhibitor

          -  You must not have received a systemic psoriasis (Ps) therapy within 4 weeks prior to
             entry into the study

          -  You must not have received a phototherapy within 4 weeks prior to entry into the study

          -  You must not have received a topical Ps therapy with psoralens within 4 weeks prior to
             entry into the study

          -  You must not be pregnant or nursing

          -  If female of childbearing potential or a male, and do not agree to use 2 forms of
             highly effective methods of birth control for at least 28 days following the last dose
             of investigational product

          -  You must not have had symptomatic herpes zoster or herpes simplex infection within 12
             weeks or have a history of disseminated/complicated herpes zoster

          -  You must not have evidence of active infection, such as fever ≥38.0ºC (100.4ºF)

          -  You must not have a history of active hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV)

          -  You must not be immunocompromised and, in the opinion of the investigator, are at an
             unacceptable risk for participating in the study

          -  You must not have known history hypogammaglobulinemia

          -  You must not have had a serious systemic or local infection within 12 weeks prior to
             entry into the study

          -  You must not have been exposed to a live vaccine within 12 weeks prior to entry into
             the study, or expected to need/receive a live vaccine (including herpes zoster
             vaccination) during the course of the study

          -  You must not have had household contact with a person with active tuberculosis (TB)
             and did not receive appropriate and documented prophylaxis for TB

          -  You must not have a serious and/or unstable illness that, in the opinion of the
             investigator, poses an unacceptable risk for the your participation in the study

          -  You must not have or have had a history of lymphoproliferative disease; or signs or
             symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy
             or splenomegaly; or active primary or recurrent malignant disease; or been in
             remission from clinically significant malignancy for less than 5 years

          -  You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse
             within the last 2 years

          -  You must not have donated blood of more than 500 mL within 4 weeks

          -  You must not have received a topical Ps treatment within 2 weeks prior to entry into
             the study

               -  Exceptions:

               -  class 6 (mild, such as desonide) or class 7 (least potent, such as
                  hydrocortisone) topical steroids used on the face, axilla, palms, soles, and/or
                  genitalia

               -  non-medicated shampoos (for example, that do not contain corticosteroids, coal
                  tar, or vitamin D3 analogues)

               -  emollients that do not contain alpha or beta hydroxyl acids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>292-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ishikawa</city>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>2308765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tochigi</city>
        <zip>329- 0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toyama</city>
        <zip>9330871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carolina</city>
        <zip>00985</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2017</results_first_posted>
  <disposition_first_submitted>January 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 25, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Plaque</keyword>
  <keyword>Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Papulosquamous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant Psoriasis Area and Severity Index (PASI) score at the conclusion of Part A stratified participants as either Responder (PASI ≥75), Partial Responder (PASI 50 - PASI 74), or Non-Responder (PASI &lt;50).</recruitment_details>
      <pre_assignment_details>Part A: Initial Treatment Period (Weeks 0 up to 12) Part B: Extension or Step-Up Period (Week 12 up to Week 24) Part C: Washout or Step-Down Period (Week 24 up to Week 40) Part D: (Re-Treatment Period up to 52 Weeks)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Placebo</title>
          <description>Placebo administered orally (PO) once daily (QD) for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Part A: Baricitinib 2 mg</title>
          <description>Baricitinib 2 milligram (mg) administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Part A: Baricitinib 4 mg</title>
          <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Part A: Baricitinib 8 mg</title>
          <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Part A: Baricitinib 10 mg</title>
          <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
        </group>
        <group group_id="P6">
          <title>Part B: Responder - Low Dose</title>
          <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
        </group>
        <group group_id="P7">
          <title>Part B: Responder - High Dose</title>
          <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
        </group>
        <group group_id="P8">
          <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
          <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
        </group>
        <group group_id="P9">
          <title>Part B: Partial-responder - Low Dose to Low Dose</title>
          <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
        </group>
        <group group_id="P10">
          <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
          <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
        </group>
        <group group_id="P11">
          <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
          <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
        </group>
        <group group_id="P12">
          <title>Part B: Placebo Extension</title>
          <description>Placebo PO QD maintained on placebo PO QD.</description>
        </group>
        <group group_id="P13">
          <title>Part C: Responder - Low Dose to Placebo</title>
          <description>Baricitinib 2 mg or 4 mg PO QD re-randomized to placebo PO QD.</description>
        </group>
        <group group_id="P14">
          <title>Part C: Responder - Low Dose to ½ Low Dose</title>
          <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 1 mg or 2 mg PO QD.</description>
        </group>
        <group group_id="P15">
          <title>Part C: Responder - High Dose to Placebo</title>
          <description>Baricitinib administered 8 mg or 10 mg PO QD re-randomized to placebo PO QD.</description>
        </group>
        <group group_id="P16">
          <title>Part C: Responder - High Dose to Low Dose</title>
          <description>Baricitinib administered 8 mg PO QD re-randomized to baricitinib 4 mg PO QD. Baricitinib administered 10 mg PO QD re-randomized to baricitinib 4 mg PO QD.</description>
        </group>
        <group group_id="P17">
          <title>Part D: Baricitinib 2 mg - Retreatment</title>
          <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
        </group>
        <group group_id="P18">
          <title>Part D: Baricitinib 4 mg - Retreatment</title>
          <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
        </group>
        <group group_id="P19">
          <title>Part D: Baricitinib 8 mg - Retreatment</title>
          <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
        </group>
        <group group_id="P20">
          <title>Part D: Baricitinib 10 mg - Retreatment</title>
          <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A: Initial Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="52">Includes participants who completed Part A, but discontinued per protocol using Part A PASI score.</participants>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued at Week 12 per protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B: Extension or Step-Up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">See Recruitment Details for explanation of Part B participant assignment.</participants>
                <participants group_id="P2" count="0">See Recruitment Details for explanation of Part B participant assignment.</participants>
                <participants group_id="P3" count="0">See Recruitment Details for explanation of Part B participant assignment.</participants>
                <participants group_id="P4" count="0">See Recruitment Details for explanation of Part B participant assignment.</participants>
                <participants group_id="P5" count="0">See Recruitment Details for explanation of Part B participant assignment.</participants>
                <participants group_id="P6" count="29">Part A participants randomized to 2 mg or 4 mg with a PASI ≥75 remained on 2 mg or 4 mg.</participants>
                <participants group_id="P7" count="64">Part A participants randomized to 8 mg or 10 mg with a PASI ≥75 remained on 8 mg or 10 mg.</participants>
                <participants group_id="P8" count="19">Placebo participants in Part A with a PASI &lt;75 were re-randomized to 8 mg or 10 mg.</participants>
                <participants group_id="P9" count="16">Part A participants randomized to 2 mg or 4 mg with a PASI ≥50 to &lt;75 remained on 2 mg or 4 mg.</participants>
                <participants group_id="P10" count="50">Part A participants randomized to 2 mg or 4 mg with a PASI &lt;50 were re-randomized to 8 mg or 10 mg.</participants>
                <participants group_id="P11" count="43">Part A 10 mg non-responders were discontinued from the study.</participants>
                <participants group_id="P12" count="8">Part A participants randomized to Placebo remained on Placebo.</participants>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="25"/>
                <participants group_id="P11" count="22"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="25"/>
                <participants group_id="P11" count="21"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Part B and Not Moving to PartC</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C: Washout or Step-Down Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0">One participant completed Part B but discontinued without receiving a Part C treatment assignment.</participants>
                <participants group_id="P6" count="0">Part A participants randomized to 2 mg or 4 mg with a PASI ≥75 remained on 2 mg or 4 mg.</participants>
                <participants group_id="P7" count="0">Part A participants randomized to 8 mg or 10 mg with a PASI ≥75 remained on 8 mg or 10 mg.</participants>
                <participants group_id="P8" count="0">Placebo participants in Part A with a PASI &lt;75 were re-randomized to 8 mg or 10 mg.</participants>
                <participants group_id="P9" count="0">Part A participants randomized to 2 mg or 4 mg with a PASI ≥50 to &lt;75 remained on 2 mg or 4 mg.</participants>
                <participants group_id="P10" count="0">Part A participants randomized to 2 mg or 4 mg with a PASI &lt;50 were re-randomized to 8 mg or 10 mg.</participants>
                <participants group_id="P11" count="0">Part A 10 mg non-responders were discontinued from the study.</participants>
                <participants group_id="P12" count="0">Part A participants randomized to Placebo remained on Placebo.</participants>
                <participants group_id="P13" count="15">Responders receiving 2 or 4 mg were re-randomized to receive placebo.</participants>
                <participants group_id="P14" count="16">Responders receiving 2 or 4 mg were re-randomized to receive half of the dose from Part B.</participants>
                <participants group_id="P15" count="55">Responders receiving 8 or 10 mg were re-randomized to receive placebo.</participants>
                <participants group_id="P16" count="55">Responders receiving 8 or 10 mg were re-randomized to receive 4 mg.</participants>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="37"/>
                <participants group_id="P16" count="18"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="10"/>
                <participants group_id="P15" count="18"/>
                <participants group_id="P16" count="37"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Qualify for Part D Per Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="14"/>
                <participants group_id="P16" count="34"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part D: Re-Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0">Responders receiving 2 or 4 mg were re-randomized to receive placebo.</participants>
                <participants group_id="P14" count="0">Responders receiving 2 or 4 mg were re-randomized to receive half of the dose from Part B.</participants>
                <participants group_id="P15" count="0">Responders receiving 8 or 10 mg were re-randomized to receive placebo.</participants>
                <participants group_id="P16" count="0">Responders receiving 8 or 10 mg were re-randomized to receive 4 mg.</participants>
                <participants group_id="P17" count="3">Responders who experienced a relapse or flare proceeded for retreatment with 2 mg.</participants>
                <participants group_id="P18" count="13">Responders who experienced a relapse or flare proceeded for retreatment with 4 mg.</participants>
                <participants group_id="P19" count="19">Responders who experienced a relapse or flare proceeded for retreatment with 8 mg.</participants>
                <participants group_id="P20" count="37">Responders who experienced a relapse or flare proceeded for retreatment with 10 mg.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="12"/>
                <participants group_id="P20" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="3"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Part A: Baricitinib 2 mg</title>
          <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Part A: Baricitinib 4 mg</title>
          <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Part A: Baricitinib 8 mg</title>
          <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Part A: Baricitinib 10 mg</title>
          <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.70" spread="15.144"/>
                    <measurement group_id="B2" value="47.81" spread="15.165"/>
                    <measurement group_id="B3" value="47.21" spread="11.650"/>
                    <measurement group_id="B4" value="47.37" spread="15.829"/>
                    <measurement group_id="B5" value="47.43" spread="10.425"/>
                    <measurement group_id="B6" value="47.31" spread="13.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Psoriasis (Ps)</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.42" spread="14.297"/>
                    <measurement group_id="B2" value="15.00" spread="9.951"/>
                    <measurement group_id="B3" value="19.90" spread="12.766"/>
                    <measurement group_id="B4" value="16.56" spread="11.948"/>
                    <measurement group_id="B5" value="16.60" spread="10.653"/>
                    <measurement group_id="B6" value="17.26" spread="11.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Body Surface Area (BSA) Affected by Psoriasis</title>
          <units>Percent of BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.18" spread="11.890"/>
                    <measurement group_id="B2" value="30.78" spread="20.523"/>
                    <measurement group_id="B3" value="28.61" spread="18.797"/>
                    <measurement group_id="B4" value="28.23" spread="15.726"/>
                    <measurement group_id="B5" value="24.45" spread="12.079"/>
                    <measurement group_id="B6" value="27.04" spread="16.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Psoriasis Area and Severity Index (PASI) Score</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.06" spread="6.805"/>
                    <measurement group_id="B2" value="21.36" spread="11.056"/>
                    <measurement group_id="B3" value="20.58" spread="9.438"/>
                    <measurement group_id="B4" value="20.24" spread="7.827"/>
                    <measurement group_id="B5" value="19.01" spread="6.177"/>
                    <measurement group_id="B6" value="20.00" spread="8.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.</description>
        <time_frame>Week 12</time_frame>
        <population>North American (NA) modified intent-to-treat (mITT) population: All NA randomized participants who received at least one dose of study drug. Non-responders and participants who discontinued study drug any time prior to time point of interest, or discontinued from study, were defined as non-responders for the non-responder imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.</description>
          <population>North American (NA) modified intent-to-treat (mITT) population: All NA randomized participants who received at least one dose of study drug. Non-responders and participants who discontinued study drug any time prior to time point of interest, or discontinued from study, were defined as non-responders for the non-responder imputation (NRI) analysis.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
        <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
          <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
          <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="29.7"/>
                    <measurement group_id="O5" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
        <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
          <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
          <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="64.1"/>
                    <measurement group_id="O3" value="47.4"/>
                    <measurement group_id="O4" value="37.5"/>
                    <measurement group_id="O5" value="24.0"/>
                    <measurement group_id="O6" value="27.9"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
        <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
        <time_frame>Week 92</time_frame>
        <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA of (0, 1) (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
          <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1 with at least a 2-point improvement from baseline in sPGA score.</description>
          <population>All randomized participants who received at least one dose of study drug. Non-Responders, as well as all participants who discontinue study treatment at any time prior to the time point of interest, were defined as Non-Responders for the NRI analysis.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.</description>
        <time_frame>Baseline Part A, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study drug. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 12 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares Means (LS Means) were calculated using an analysis of covariance (ANCOVA) model on the last observation carried forward (LOCF) with treatment group as a fixed effect and baseline PASI score as a continuous covariate.</description>
          <population>All randomized participants who received at least one dose of study drug. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="1.370"/>
                    <measurement group_id="O2" value="9.40" spread="1.413"/>
                    <measurement group_id="O3" value="9.46" spread="0.941"/>
                    <measurement group_id="O4" value="11.52" spread="0.997"/>
                    <measurement group_id="O5" value="13.93" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
        <time_frame>Baseline Part A, Week 24</time_frame>
        <population>All randomized participants who received at least one dose of study drug and at least 1 post-baseline observation in Part A at or prior to week 24. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Part A in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 24 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis: Measure: Psoriasis Area and Severity Index [PASI])</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
          <population>All randomized participants who received at least one dose of study drug and at least 1 post-baseline observation in Part A at or prior to week 24. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.62" spread="5.480"/>
                    <measurement group_id="O2" value="16.69" spread="7.399"/>
                    <measurement group_id="O3" value="12.94" spread="6.711"/>
                    <measurement group_id="O4" value="12.23" spread="7.510"/>
                    <measurement group_id="O5" value="14.55" spread="10.493"/>
                    <measurement group_id="O6" value="13.67" spread="9.966"/>
                    <measurement group_id="O7" value="13.43" spread="5.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
        <time_frame>Baseline Part D, Week 92</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug and has 1 post-baseline observation at or prior to week 92. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Part D in Mean Psoriasis Area and Severity Index (PASI) Total Score to Week 92 (Efficacy of Baricitinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease.</description>
          <population>All randomized participants who received ≥1 dose of study drug and has 1 post-baseline observation at or prior to week 92. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="2.836"/>
                    <measurement group_id="O2" value="3.25" spread="4.447"/>
                    <measurement group_id="O3" value="5.84" spread="5.544"/>
                    <measurement group_id="O4" value="6.98" spread="6.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12</title>
        <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline Part A, Week 12</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 12</title>
          <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.98"/>
                    <measurement group_id="O2" value="-3.4" spread="1.00"/>
                    <measurement group_id="O3" value="-4.6" spread="0.67"/>
                    <measurement group_id="O4" value="-4.0" spread="0.71"/>
                    <measurement group_id="O5" value="-5.1" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24</title>
        <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
        <time_frame>Baseline Part A, Week 24</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part B and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Dermatology Life Quality Index (DLQI) Total Score to Week 24</title>
          <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part B and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="7.53"/>
                    <measurement group_id="O2" value="-7.0" spread="8.18"/>
                    <measurement group_id="O3" value="-3.8" spread="6.27"/>
                    <measurement group_id="O4" value="-1.5" spread="5.92"/>
                    <measurement group_id="O5" value="-7.8" spread="6.89"/>
                    <measurement group_id="O6" value="-4.5" spread="8.99"/>
                    <measurement group_id="O7" value="-3.5" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92</title>
        <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
        <time_frame>Baseline Part D, Week 92</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part D in Dermatology Life Quality Index (DLQI) Total Score to Week 92</title>
          <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline DLQI observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="4.93"/>
                    <measurement group_id="O2" value="-0.5" spread="3.62"/>
                    <measurement group_id="O3" value="-2.1" spread="7.40"/>
                    <measurement group_id="O4" value="-5.0" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12</title>
        <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline Part A, Week 12</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score at Week 12</title>
          <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.48"/>
                    <measurement group_id="O2" value="-2.8" spread="0.49"/>
                    <measurement group_id="O3" value="-3.3" spread="0.33"/>
                    <measurement group_id="O4" value="-3.8" spread="0.35"/>
                    <measurement group_id="O5" value="-4.7" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24</title>
        <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
        <time_frame>Baseline Part A, Week 24</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Itch Numeric Rating Scale (Itch NRS) Score to Week 24</title>
          <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="3.52"/>
                    <measurement group_id="O2" value="-5.6" spread="2.96"/>
                    <measurement group_id="O3" value="-5.4" spread="3.83"/>
                    <measurement group_id="O4" value="-3.4" spread="3.69"/>
                    <measurement group_id="O5" value="-4.1" spread="3.33"/>
                    <measurement group_id="O6" value="-3.5" spread="3.03"/>
                    <measurement group_id="O7" value="-2.5" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92</title>
        <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
        <time_frame>Baseline Part D, Week 92</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part D in Itch Numeric Rating Scale (Itch NRS) Score to Week 92</title>
          <description>The Itch NRS is a participant-administered, 11‑point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline Itch NRS observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="0.58"/>
                    <measurement group_id="O2" value="-2.5" spread="3.23"/>
                    <measurement group_id="O3" value="-2.7" spread="2.91"/>
                    <measurement group_id="O4" value="-3.1" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12</title>
        <description>The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline Part A, Week 12</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score at Week 12</title>
          <description>The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.57"/>
                    <measurement group_id="O2" value="-1.0" spread="0.58"/>
                    <measurement group_id="O3" value="-1.0" spread="0.39"/>
                    <measurement group_id="O4" value="-0.7" spread="0.40"/>
                    <measurement group_id="O5" value="-0.9" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24</title>
        <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
        <time_frame>Baseline Part A, Week 24</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. As observed values were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Placebo administered PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 24</title>
          <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. As observed values were used.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.48"/>
                    <measurement group_id="O2" value="-2.6" spread="3.80"/>
                    <measurement group_id="O3" value="-1.4" spread="3.15"/>
                    <measurement group_id="O4" value="-1.2" spread="2.67"/>
                    <measurement group_id="O5" value="-1.6" spread="2.99"/>
                    <measurement group_id="O6" value="-2.2" spread="4.64"/>
                    <measurement group_id="O7" value="-3.0" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92</title>
        <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
        <time_frame>Baseline Part D, Week 92</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part D in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score to Week 92</title>
          <description>The QIDS-SR16 is a 16-item, self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (APA 1994). A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline QIDS-SR16 observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.25" spread="1.708"/>
                    <measurement group_id="O3" value="-0.13" spread="3.796"/>
                    <measurement group_id="O4" value="-0.86" spread="2.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
        <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline Part A, Week 12</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. As observed values were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Part A: Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
          <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome. LS Means were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. As observed values were used.</population>
          <units>Millimeter (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.55"/>
                    <measurement group_id="O2" value="5.7" spread="2.46"/>
                    <measurement group_id="O3" value="6.4" spread="1.62"/>
                    <measurement group_id="O4" value="9.5" spread="1.71"/>
                    <measurement group_id="O5" value="7.8" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
        <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
        <time_frame>Baseline Part A, Week 24</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. As observed values were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Responder - Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD maintained at baricitinib 2 mg or 4 mg PO QD, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Responder - High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD maintained at baricitinib 8 mg or 10 mg PO QD, respectively.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Partial- and Non-responder - Placebo to High Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Partial-responder - Low Dose to Low Dose</title>
            <description>Baricitinib administered 2 mg or 4mg PO QD. Randomized to remain on the same dose.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Partial- and Non-responder - Low Dose to High Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Partial- and Non-responder - High Dose to High Dose</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo Extension</title>
            <description>Placebo PO QD maintained on placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part A in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
          <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. As observed values were used.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="11.41"/>
                    <measurement group_id="O2" value="13.2" spread="22.06"/>
                    <measurement group_id="O3" value="9.6" spread="10.78"/>
                    <measurement group_id="O4" value="9.4" spread="20.95"/>
                    <measurement group_id="O5" value="7.5" spread="14.47"/>
                    <measurement group_id="O6" value="10.5" spread="19.94"/>
                    <measurement group_id="O7" value="7.8" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
        <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
        <time_frame>Baseline Part D, Week 92</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Baricitinib 2 mg - Retreatment</title>
            <description>Baricitinib 2 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Baricitinib 4 mg - Retreatment</title>
            <description>Baricitinib 4 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Baricitinib 8 mg - Retreatment</title>
            <description>Baricitinib 8 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Baricitinib 10 mg - Retreatment</title>
            <description>Baricitinib 10 mg administrated PO QD (retreatment with Part B efficacious dose) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Part D in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scores</title>
          <description>The EQ-5D-5L is a standardized measure of health status of the participant. One of two portions of the EQ-5D-5L was used in which a self-perceived health score is assessed using a visual analogue scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the &quot;worst health you can imagine&quot; and 100 mm indicated the &quot;best health you can imagine&quot;. This information is used as a quantitative measure of health outcome.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and had ≥1 evaluable post-baseline EQ-5D-5L observation. Missing values were imputed with the last observation carried forward (LOCF) method.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="10.263"/>
                    <measurement group_id="O2" value="4.00" spread="26.920"/>
                    <measurement group_id="O3" value="4.78" spread="13.571"/>
                    <measurement group_id="O4" value="4.19" spread="19.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C</title>
        <description>Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score &gt;125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.</description>
        <time_frame>Week 40</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A and participated in Part C.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Responder - Low Dose to Placebo</title>
            <description>Baricitinib 2 mg or 4 mg PO QD re-randomized to placebo PO QD.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Responder - Low Dose to ½ Low Dose</title>
            <description>Baricitinib administered 2 mg or 4 mg PO QD re-randomized to baricitinib 1 mg or 2 mg PO QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Responder - High Dose to Placebo</title>
            <description>Baricitinib administered 8 mg or 10 mg PO QD re-randomized to placebo PO QD.</description>
          </group>
          <group group_id="O4">
            <title>Part C: Responder - High Dose to Low Dose</title>
            <description>Baricitinib administered 8 mg PO QD re-randomized to baricitinib 4 mg PO QD. Baricitinib administered 10 mg PO QD re-randomized to baricitinib 4 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Rebound Upon Discontinuation of Study Drug in Part C</title>
          <description>Rebound was defined as worsening of psoriasis compared to baseline at Week 0 (for example, PASI score &gt;125% of baseline value) or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of stopping study drug.</description>
          <population>All randomized participants who received ≥1 dose of study drug in Part A and participated in Part C.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib</title>
        <time_frame>Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A, had evaluable PK, and participated in Part C. Some participants received 4mg or 8 mg and increased to 8mg or 10 mg, depending on the response at week 12. Those participants are treated as separate participants in each dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib</title>
          <population>All randomized participants who received ≥1 dose of study drug in Part A, had evaluable PK, and participated in Part C. Some participants received 4mg or 8 mg and increased to 8mg or 10 mg, depending on the response at week 12. Those participants are treated as separate participants in each dose group.</population>
          <units>nanomole (nM)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="24.7"/>
                    <measurement group_id="O2" value="106" spread="25.9"/>
                    <measurement group_id="O3" value="222" spread="24.4"/>
                    <measurement group_id="O4" value="260" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)</title>
        <time_frame>Day 1:15 minutes(m) to 30m and 1hour(h) to 3h Postdose; Week 1:Predose; Week 4:Predose; Week 8:Predose; 15m to 30m and 1h to 3h Postdose, Week 12:Predose; Weeks 14 and 20; Week 24:Predose; Week 28; Week 40. If applicable: Weeks 4, 24, and 52 Post-Relapse</time_frame>
        <population>All randomized participants who received ≥1 dose of study drug in Part A, had evaluable PK, and participated in Part A, B or C. Some participants received 4mg or 8 mg and increased to 8mg or 10 mg, depending on the response at week 12. Those participants are treated as separate participants in each dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib 2 mg</title>
            <description>Baricitinib 2 milligram (mg) administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Baricitinib 4 mg</title>
            <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Baricitinib 8 mg</title>
            <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Baricitinib 10 mg</title>
            <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration-Time Curve Versus Time During One Dosing Interval at Steady State (AUC τ,ss)</title>
          <population>All randomized participants who received ≥1 dose of study drug in Part A, had evaluable PK, and participated in Part A, B or C. Some participants received 4mg or 8 mg and increased to 8mg or 10 mg, depending on the response at week 12. Those participants are treated as separate participants in each dose group.</population>
          <units>nanomole*hour (nM*h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" spread="40.7"/>
                    <measurement group_id="O2" value="975" spread="41.1"/>
                    <measurement group_id="O3" value="2030" spread="43.3"/>
                    <measurement group_id="O4" value="2440" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Placebo administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Part A: Baricitinib 2 mg</title>
          <description>Baricitinib 2 milligram administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Part A: Baricitinib 4 mg</title>
          <description>Baricitinib 4 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 8 mg or 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Part A: Baricitinib 8 mg</title>
          <description>Baricitinib 8 mg administered PO QD for initial 12 weeks. At Week 12, depending on participant's response, dose could be increased to baricitinib 10 mg PO QD for an additional 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Part A: Baricitinib 10 mg</title>
          <description>Baricitinib 10 mg administered PO QD for initial 12 weeks. At Week 12, participants who did not achieve at least a PASI 50 were discontinued from the study.</description>
        </group>
        <group group_id="E6">
          <title>Part B: Placebo</title>
          <description>Placebo PO QD maintained on placebo PO QD.</description>
        </group>
        <group group_id="E7">
          <title>Part B: Low Dose</title>
          <description>All participants in the following groups (as described in the Participant Flow):
Responder Low Dose
Partial Responder Low Dose to Low Dose groups.</description>
        </group>
        <group group_id="E8">
          <title>Part B: High Dose</title>
          <description>All participants in the following groups (as described in the Participant Flow):
Responder High Dose
Partial and Non-responder Placebo to High Dose
Partial and Non-responder Low Dose to High Dose
Partial and Non-responder High Dose to High Dose</description>
        </group>
        <group group_id="E9">
          <title>Part C: Placebo</title>
          <description>All placebo participant groups after study drug re-randomized.</description>
        </group>
        <group group_id="E10">
          <title>Part C: Baricitinib</title>
          <description>All baricitinib participant groups after study drug re-randomized to various doses.</description>
        </group>
        <group group_id="E11">
          <title>Part D: All Baricitinib Doses</title>
          <description>All participant dosages following baricitinib retreatment with Part B efficacious dose for 52 weeks.</description>
        </group>
        <group group_id="E12">
          <title>Follow-up: Always Placebo</title>
          <description>Participants in follow-up with exposure to placebo only during the study. No placebo received during follow-up.</description>
        </group>
        <group group_id="E13">
          <title>Follow-up: Ever Used Baricitinib</title>
          <description>Participants in follow-up with exposure to any dose of baricitinib during study. No baricitinib received during follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="176"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E11" subjects_affected="37" subjects_at_risk="72"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E11" events="14" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Salpingo-oophorectomy bilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

